产业高质量发展，不出意外再度成为各地节后第一天的"关键词" 从省份来看，广东连续四年将高质量发展大会作为"新春第一会"，今年聚焦制造业和服务业协同发展； 浙江则再次将"高质量发展建设共同富裕示范区"作为主题，以求回答"推动发展红利惠及千家万户"之 问。 作为省内"领头羊"，不少经济强市也已开跑。将冲刺"全国增长极"作为目标的成都，"新春第一会"同样 剑指高质量发展，又颇具特色——2月24日，成都召开推进重点产业链高质量发展工作会议，以重点产 业链建圈强链破题，无疑为高质量发展锚定了更为具体的承载。 推动成都能级提升，重点产业链作用不容小觑。去年，成都GDP达到2.48万亿元、增长5.8%，在近2.5 万亿元的经济体量上实现"高位增长"；其中，产业突围格外引人瞩目：成都在2个万亿级产业集群的基 础上，千亿级产业链增至13条，同时，国家先进制造业集群、国家中小企业特色产业集群数量均位居副 省级城市第二。 会上，成都亮出目标：今年作为"十五五"规划开局之年，成都将推动4条产业链迈上新的千亿台阶，其 中软件和信息服务业营收突破9000亿元。由此，成都将向第三个万亿产业集群挺进。站上新起点、面对 新挑战，成都将如何谋局 ...

Group 1 - The stock price of Dongcheng Pharmaceutical closed at 17.51 yuan on August 26, down by 0.10 yuan, a decrease of 0.57% from the previous trading day [1] - The trading volume on that day was 139,300 hands, with a total transaction amount of 246 million yuan [1] - The stock reached a high of 17.92 yuan and a low of 17.45 yuan during the day, with a fluctuation of 2.67% [1] Group 2 - Dongcheng Pharmaceutical operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of heparin raw materials and preparations, as well as nuclear medicine products [1] - For the first half of 2025, the company reported an operating income of 1.384 billion yuan and a net profit attributable to shareholders of 88.65 million yuan [1] Group 3 - On August 26, the company announced two personnel changes: Vice General Manager Wu Xiaoming resigned due to work adjustments but will continue to serve as the Executive Director and General Manager of its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. [1] - Securities Affairs Representative Li Ji also resigned due to work adjustments, continuing as Executive Director and Secretary of the Board for the same subsidiary [1] Group 4 - On August 26, the net outflow of main funds was 19.8413 million yuan, with a cumulative net outflow of 4.1302 million yuan over the past five days [1]